

FELINE AORTIC THROMBOEMBOLISM: PREVENTION AND NOVEL ACUTE MANAGEMENT APPROACHES


BACKGROUND

- ATE is more common in cats than any other species, comprising 79-85% of their arterial thromboembolism cases.
- Survival rates are low, ranging from 14-40% when there is a bilateral pelvic limb infarction.
- CMs account for 90% of ATE cases, especially HCM.
- 5-21% of cats with HCM suffer from ATE.

Abbreviations: ATE = aortic thromboembolism; CM = cardiomyopathy; HCM = hypertrophic cardiomyopathy; LAD = left atrial dilation; LAA = left atrial appendage; LMWHs = low molecular weight heparins; NOACs = new oral anticoagulants; UFHs = unfractionated heparins.


OBJECTIVES

- To perform a review on the state of the art of ATE's acute management and preventive approaches.
- Analyse the effectiveness of the current standard of care and the available alternatives.



PREVENTION

1. Doppler echocardiography to define risk:



Moderate to severe LAD:

- LA:Ao > 1.9-2
 - LA diameter > 17-20 mm
- Blood flow velocities <0.20 m/s in the LAA.**
- Spontaneous echocontrast (SEC) or intracardiac thrombus**
- +/- Previous history of ATE

Figure: Right parasternal short-axis view of a cat with restrictive CM and severe LAD and SEC (white arrows). LA (Left atrium); Ao (Aorta) (Chetboul et al. 2019) [Modified].

2. Criteria for treatment application

Moderate risk	High risk
CMs Hyperthyroidism Pulmonary neoplasia OR LAD, SEC, low blood flow in the LAA	Predisposing disease + risk factor/s
Recommendation	Indication

OBJECTIVE

Postpone ATE onset or recurrence

3. Thromboprophylactic treatment

ANTICOAGULANTS	+	ANTIPLATELET AGENTS
LMWHs (enoxaparin/dalteparin): • Subcutaneous administration NOACs (rivaroxaban/apixaban): • Oral administration • Requires further studies in cats		Clopidogrel: • Oral administration • Proved to reduce ATE recurrence and cardiac death.

ACUTE MANAGEMENT

Antithrombotic therapy: current standard of care

- **Induction of a hypocoagulable state: UFHs** prevents further embolus growth and microcirculation thrombosis.
 - **Improvement of collateral blood flow: clopidogrel (75 mg)** avoids the release of vasoactive substances.
- OUTCOME:** survival rates of 31-45% in cats with arterial thromboembolism.
- **Sufficient** in cats with a **single limb infarcted**.
 - **Insufficient** in cats with **≥ 2 limbs infarcted**.
 - **Euthanasia at presentation** in 25-61% of patients.
 - **Same risk of reperfusion syndrome** as infarction resolution.


Acute thrombus resolution: not common practice

Thromboembolus interventionism

- **Surgical thromboembolectomy:** through aortotomy.
 - **Rheolytic thromboembolectomy:** through percutaneous aspiration.
- Treatment of choice in humans with ATE.
- Counted cases in cats, but successful.

Systemic thrombolysis - Tissue Plasminogen Activator

- Marginally superior to antithrombotic therapy.
- Survival notably increases in high-dose protocols (77.8%).
- Cost may preclude its use.



- CONCLUSIONS -

- ✓ The detection of LAD, SEC and low blood flow velocities in the LAA can successfully predict ATE risk.
- ✓ The protocolisation of Doppler echocardiography in target patients and thromboprophylaxis prescription may significantly reduce ATE onset.
- ✓ Acute thrombus resolution techniques seem promising for cats with multiple limb infarction since they do not respond to antithrombotics.
- ✓ Early intervention of thrombus is crucial for survival, and its implementation in protocols could reduce euthanasia rates at presentation.
- ✓ Further studies are required to confirm the best multimodal thromboprophylactic therapy upon NOACs' normalisation and to evaluate the outcome of thrombus resolution techniques once refined and protocolised.